Deferred treatment with sofosbuvir-velpatasvir-voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1 | HCV Guidance

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

Deferred treatment with sofosbuvir-velpatasvir-voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1

Bourliere M, Gordon SC, Schiff ER, et al. Deferred treatment with sofosbuvir-velpatasvir-voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1. Lancet Gastroenterol Hepatol. 2018;3(9):559-565.

Publication Type:

Journal Article

Authors:

Bourliere, M.; Gordon, S.C.; Schiff, Eugene R.; et, al

Source:

Lancet Gastroenterol Hepatol, Volume 3, Issue 9, p.559-565 (2018)

Cited On:

Sofosbuvir-Based and Elbasvir/Grazoprevir Treatment Failures

Export Citation:

RIS Format

Top